These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

723 related articles for article (PubMed ID: 32835657)

  • 1. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
    Ge T; Liu T; Guo L; Chen Z; Lou G
    Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
    Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
    Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
    Zhang Y; Huang S; Guo Y; Li L
    Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.
    Yan M; Yang X; Shen R; Wu C; Wang H; Ye Q; Yang P; Zhang L; Chen M; Wan B; Zhang Q; Xia S; Lu X; Shao G; Zhou X; Yu J; Shao Q
    Cell Death Dis; 2018 Nov; 9(11):1123. PubMed ID: 30409964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition.
    Cao L; Wan Q; Li F; Tang CE
    BMB Rep; 2018 Sep; 51(9):456-461. PubMed ID: 30037365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
    Wu D; Lu P; Mi X; Miao J
    Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling.
    Tan WX; Sun G; Shangguan MY; Gui Z; Bao Y; Li YF; Jia ZH
    Sci Rep; 2020 Sep; 10(1):14768. PubMed ID: 32901049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMAD3 inducing the transcription of  STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel.
    Shi Y; Zhang J; Liu M; Huang Y; Yin L
    J Cell Biochem; 2019 Jun; 120(6):10796-10811. PubMed ID: 30701575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer.
    Wu X; Zhao J; Ruan Y; Sun L; Xu C; Jiang H
    Cell Death Dis; 2018 Oct; 9(11):1102. PubMed ID: 30375371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving.
    Wang DY; Li N; Cui YL
    Cancer Res Treat; 2020 Jul; 52(3):798-814. PubMed ID: 32124583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
    Wang J; Liu L
    J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-139-5p affects cisplatin sensitivity in human nasopharyngeal carcinoma cells by regulating the epithelial-to-mesenchymal transition.
    Shao Q; Zhang P; Ma Y; Lu Z; Meng J; Li H; Wang X; Chen D; Zhang M; Han Y; Liu H; Ma S
    Gene; 2018 Apr; 652():48-58. PubMed ID: 29427737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-99a suppressed cell proliferation and invasion by directly targeting HOXA1 through regulation of the AKT/mTOR signaling pathway and EMT in ovarian cancer.
    Zhang L; Liu XL; Yuan Z; Cui J; Zhang H
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4663-4672. PubMed ID: 31210292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B.
    Niu Q; Liu Z; Gao J; Wang Q
    Yonsei Med J; 2019 Dec; 60(12):1146-1156. PubMed ID: 31769245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA SNHG6 knockdown inhibits cisplatin resistance and progression of gastric cancer through miR-1297/BCL-2 axis.
    Mei J; Liu G; Li R; Xiao P; Yang D; Bai H; Hao Y
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34821362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3β/β-catenin signaling pathway.
    Dai J; Wei R; Zhang P; Kong B
    J Transl Med; 2019 Jun; 17(1):190. PubMed ID: 31171023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
    Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K
    Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
    Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
    Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.
    Guo J; Jin D; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Miao S; Xi S
    EBioMedicine; 2018 Sep; 35():204-221. PubMed ID: 30146342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.